Showing results (11-20 of 67) with videos related to
Sort By:
Pageof 7
European Urology|August 6, 2013
Side effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCGMaurizio Brausi, Jorg Oddens, Richard Sylvester, et al.The Oncologist|May 2, 2008
A phase II study of gefitinib for patients with advanced HER-1 expressing synovial sarcoma refractory to doxorubicin-containing regimensIsabelle Ray-Coquard, Axel Le Cesne, Jeremy S Whelan, et al.European Journal of Nuclear Medicine and Molecular Imaging|February 26, 2015
Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trialIvalina Hristova, Ronald Boellaard, Wouter Vogel, et al.The Oncologist|April 14, 2018
Outcomes of Elderly Patients with Advanced Soft Tissue Sarcoma Treated with First-Line Chemotherapy: A Pooled Analysis of 12 EORTC Soft Tissue and Bone Sarcoma Group TrialsEugenie Younger, Saskia Litière, Axel Le Cesne, et al.Clinical Sarcoma Research|August 5, 2014
Pazopanib in advanced desmoplastic small round cell tumours: a multi-institutional experienceAnna Maria Frezza, Charlotte Benson, Ian R Judson, et al.European Urology|November 13, 2012
Final results of an EORTC-GU cancers group randomized study of maintenance bacillus Calmette-Guérin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenanceJorg Oddens, Maurizio Brausi, Richard Sylvester, et al.European Urology|December 28, 2010
A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinomaHendrik Van Poppel, Luigi Da Pozzo, Walter Albrecht, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 25, 2012
Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983Ronald de Wit, Iwona Skoneczna, Gedske Daugaard, et al.Lung Cancer (Amsterdam, Netherlands)|January 15, 2026
Nintedanib as switch maintenance treatment in malignant pleural mesothelioma (NEMO): A double-blind randomized phase II trial (EORTC-08112-LCG)Omar Abdel-Rahman, Paul Taylor, Mary O'Brien, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)Stefan Sleijfer, Isabelle Ray-Coquard, Zsuzsa Papai, et al.Pageof 7